Literature DB >> 25787865

CriticalSorb™: enabling systemic delivery of macromolecules via the nasal route.

Andrew L Lewis1, Faron Jordan, Lisbeth Illum.   

Abstract

Systemic delivery of proteins via the nasal route has to date been limited by their poor absorption across the nasal mucosa, and the less than optimal tolerability of known permeation enhancers. We have recently developed a highly effective nasal delivery system (CriticalSorb™) based on Solutol HS15. Extensive toxicology studies have shown CriticalSorb™ to be very well tolerated, non-toxic and non-irritant. Cell culture and ex vivo-isolated tissue studies have shown it to promote transport of molecules mainly via transcellular but also to some extent, via paracellular routes. Pharmacokinetic/pharmacodynamic studies in rats, rabbits, non-human primates and recently in man have demonstrated significantly enhanced systemic delivery of nasally administered proteins including insulin (~6 kDa) and human growth hormone (~22 kDa), and pharmacodynamics similar to those after subcutaneous injection. CriticalSorb™ therefore opens up the possibility of developing nasal spray formulations for macromolecules such as proteins.

Entities:  

Year:  2013        PMID: 25787865     DOI: 10.1007/s13346-012-0089-8

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  23 in total

1.  A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.

Authors:  E A McNeela; D O'Connor; I Jabbal-Gill; L Illum; S S Davis; M Pizza; S Peppoloni; R Rappuoli; K H Mills
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

2.  A survey of children's preferences for influenza vaccine attributes.

Authors:  Emuella M Flood; Kellie J Ryan; Matthew D Rousculp; Kathleen M Beusterien; Stan L Block; Matthew C Hall; Parthiv J Mahadevia
Journal:  Vaccine       Date:  2011-04-19       Impact factor: 3.641

3.  Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a.

Authors:  Kingston H G Mills; Catherine Cosgrove; Edel A McNeela; Amy Sexton; Rafaela Giemza; Inderjit Jabbal-Gill; Anne Church; Wu Lin; Lisbeth Illum; Audino Podda; Rino Rappuoli; Mariagrazia Pizza; George E Griffin; David J M Lewis
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

4.  Effective nasal influenza vaccine delivery using chitosan.

Authors:  Robert C Read; Simone C Naylor; Christopher W Potter; Jenny Bond; Inderjit Jabbal-Gill; Anthony Fisher; Lisbeth Illum; Roy Jennings
Journal:  Vaccine       Date:  2005-08-15       Impact factor: 3.641

5.  Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations.

Authors:  Yu-Hui Cheng; A Margaret Dyer; Inderjit Jabbal-Gill; Michael Hinchcliffe; Richard Nankervis; Alan Smith; Peter Watts
Journal:  Eur J Pharm Sci       Date:  2005-09       Impact factor: 4.384

6.  Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.

Authors:  A Bacon; J Makin; P J Sizer; I Jabbal-Gill; M Hinchcliffe; L Illum; S Chatfield; M Roberts
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

7.  Intranasal delivery of morphine.

Authors:  L Illum; P Watts; A N Fisher; M Hinchcliffe; H Norbury; I Jabbal-Gill; R Nankervis; S S Davis
Journal:  J Pharmacol Exp Ther       Date:  2002-04       Impact factor: 4.030

8.  Intravail: highly effective intranasal delivery of peptide and protein drugs.

Authors:  Edward T Maggio
Journal:  Expert Opin Drug Deliv       Date:  2006-07       Impact factor: 6.648

9.  CriticalSorb™ promotes permeation of flux markers across isolated rat intestinal mucosae and Caco-2 monolayers.

Authors:  D J Brayden; V A Bzik; A L Lewis; L Illum
Journal:  Pharm Res       Date:  2012-05-26       Impact factor: 4.200

10.  Creation of a standardized geometry of the human nasal cavity.

Authors:  Y Liu; M R Johnson; E A Matida; S Kherani; J Marsan
Journal:  J Appl Physiol (1985)       Date:  2009-01-08
View more
  4 in total

1.  Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers.

Authors:  Andrew L Lewis; Faron Jordan; Tina Patel; Kirk Jeffery; Gareth King; Martin Savage; Stephen Shalet; Lisbeth Illum
Journal:  J Clin Endocrinol Metab       Date:  2015-10-01       Impact factor: 5.958

Review 2.  Phospholipid Vesicles for Dermal/Transdermal and Nasal Administration of Active Molecules: The Effect of Surfactants and Alcohols on the Fluidity of Their Lipid Bilayers and Penetration Enhancement Properties.

Authors:  Hiba Natsheh; Elka Touitou
Journal:  Molecules       Date:  2020-06-27       Impact factor: 4.411

3.  Development and in vivo evaluation of intranasal formulations of parathyroid hormone (1-34).

Authors:  Dan Wang; Yimeng Du; Wenpeng Zhang; Xiaolu Han; Hui Zhang; Zengming Wang; Nan Liu; Meng Li; Xiang Gao; Xiaomei Zhuang; Jing Gao; Aiping Zheng
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

4.  Development and Optimization of Chitosan Nanoparticle-Based Intranasal Vaccine Carrier.

Authors:  Xiaoyi Gao; Nan Liu; Zengming Wang; Jing Gao; Hui Zhang; Meng Li; Yimeng Du; Xiang Gao; Aiping Zheng
Journal:  Molecules       Date:  2021-12-29       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.